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for nuclear actin polymerization in coordinating
nucleocapsid morphogenesis and membrane-
capsid interactions during virion assembly.
AcMNPV has evolved exquisite control over
the actin cytoskeleton of its host cell, manipulat-
ing both activity and localization of the Arp2/3
complex to promote dynamic nuclear actin po-
lymerization that is essential for proper virion
processing and infectivity. Given the conservation
of p78/83 among lepidopteran NPVs (13, 17), it
is likely that these viruses use the same mech-
anism for nuclear actin polymerization. It seems
quite possible that other unrelated pathogens have
also evolved similar strategies for exploiting nu-
clear actin (18). Because pathogens rarely invent
cell biological processes, preferring to adapt exist-
ing pathways to their own needs, we suggest that
AcMNPV may have co-opted existing nuclear
functions and regulatory mechanisms of actin to
facilitate its replication.
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S6K1- and bTRCP-Mediated
Degradation of PDCD4 Promotes
Protein Translation and Cell Growth
N. Valerio Dorrello,1* Angelo Peschiaroli,1* Daniele Guardavaccaro,1 Nancy H. Colburn,2
Nicholas E. Sherman,3 Michele Pagano1†
The tumor suppressor programmed cell death protein 4 (PDCD4) inhibits the translation initiation
factor eIF4A, an RNA helicase that catalyzes the unwinding of secondary structure at the 5¶
untranslated region (5¶UTR) of messenger RNAs (mRNAs). In response to mitogens, PDCD4 was
rapidly phosphorylated on Ser67 by the protein kinase S6K1 and subsequently degraded via the
ubiquitin ligase SCFbTRCP. Expression in cultured cells of a stable PDCD4 mutant that is unable to
bind bTRCP inhibited translation of an mRNA with a structured 5¶UTR, resulted in smaller cell size,
and slowed down cell cycle progression. We propose that regulated degradation of PDCD4 in
response to mitogens allows efficient protein synthesis and consequently cell growth.
T
he proteolysis of many cellular regulators
is controlled by SCF (SKP1–CUL1–F-box
protein) ubiquitin ligases (1). In humans,
there are 68 SCF ligases (2), each characterized
by a different F-box protein subunit that provides
specificity by directly recruiting the substrate.
Mammals express two distinct paralogs of the
F-box protein bTRCP (bTRCP1 and bTRCP2),
with biochemical properties that are indistin-
guishable. We will therefore use the term bTRCP
to refer to both, unless specified.
To identify new substrates of the SCFbTRCP
ubiquitin ligase, we used an immunopurification
strategy that enriches for ubiquitylated sub-
strates, followed by mass spectrometry analy-
sis (3). In addition to peptides derived from known
Fig. 4. p78/83 activation of Arp2/3 complex is required for NPV-induced
nuclear actin polymerization. (A) F-actin and p78/83 in TN-368 cells transfected
with the indicated bacmids. Cells were fixed 24 hpt and stained with DAPI,
Alexa 488–phalloidin, and p78/83 antibodies. Scale bar, 10 mm. (B)
Quantification of the imaging in (A). (Top) Scatter plot of the ratio of average
nuclear-to-cytoplasmic F-actin intensity in individual transfected cells (n from
65 to 250) for each p78/83 variant. (Bottom) Percentage of transfected cells
with nuclear-to-cytoplasmic F-actin ratio 91.5 for each p78/83 variant. (C)
Transmission electron microscopy of viral particles formed in the nuclei of TN-
368 cells transfected with WT (left) or DE284-5AA (right) bacmids.
Nucleocapsids (nc), envelope (e), free membranes (m). Scale bar, 200 nm.
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SCFbTRCP substrates, we also recovered three pep-
tides corresponding to programmed cell death
protein 4 (PDCD4), not previously identified as an
SCFbTRCP substrate.
PDCD4 is a tumor suppressor protein that is
lost in certain aggressive human carcinomas and
whose expression inhibits transformation in
cultured cells and in a mouse model of tu-
morigenesis Ereviewed in (4) and (5)^. PDCD4
binds the eukaryotic translation initiation factor
(eIF) 4A (6–8), an RNA helicase that catalyzes
the unwinding of mRNA secondary structure at
the 5¶ untranslated region (5¶UTR). PDCD4 also
binds eIF4G (7, 9) and is thought to prevent
translation by competing with eIF4G for binding
to eIF4A, or inhibiting eIF4A_s helicase activity,
or both.
Because protein translation is stimulated by
mitogens, we examined their impact on the abun-
dance of PDCD4. Human T98G cells (revertants
from T98 glioblastoma cells that acquired the
property to accumulate in G0/G1 in low serum)
and normal human fibroblasts were deprived of
serum for 72 hours and then reactivated by
addition of serum. In mitogen-deprived cells,
the overall amount of PDCD4 increased, but
after mitogen stimulation, it rapidly decreased
(Fig. 1A and fig. S1). Treatment of the cells
with the proteasome inhibitor MG132 pre-
vented the disappearance of PDCD4 (Fig. 1B).
Fig. 1. Rapid degradation of PDCD4 in response to mitogens via the mTOR-S6K1
pathway. (A) T98G cells were either grown in the presence of serum (S) or deprived of
serum (SD) for 72 hours. After this period, serum was added (SA), and cells were
collected at the indicated times. Protein extracts were analyzed by immunoblotting
with antibodies to the indicated proteins. (B) The experiment was performed as in (A),
except that during the last 4 hours before harvesting, cells were treated with either
dimethyl sulfoxide (DMSO) or MG132. (C) The experiment was performed as in (A),
except that, together with serum, various drugs were added, as indicated.
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Fig. 2. PDCD4 degradation and binding to bTRCP requires the DSGXX(X)S
degron and is stimulated by phosphorylation on Ser67. (A) HEK293T cells were
transfected with an empty vector (EV), HA-tagged wild-type PDCD4 (WT), different
HA-tagged mutants (as indicated), or HA-tagged b-catenin (a known bTRCP
substrate). In all cases, FLAG-tagged bTRCP1 was also cotransfected. Whole-cell ex-
tracts (WCE) were subjected either to immunoblotting directly or to immunoprecipi-
tation (IP) with a HA-specific resin, followed by immunoblotting with antibodies to the
indicated proteins. (B) 35S-labeled in vitro translated bTRCP1, FBXW5, and FBXW7
were used in binding reactions with beads coupled to the PDCD4 peptide
K65NSSRDSGRGDSVSD79 or the phosphopeptide K65NSSRDpSGRGDpSVSD79. Bound proteins were eluted and subjected to electrophoresis and autoradiography.
(C) T98G cells infected with a retrovirus expressing HA-tagged PDCD4 were deprived of serum (SD) for 72 hours and then activated with serum for 1 hour
(SA). Cells were treated with MG132 for 3 hours before harvesting and lysis, and extracts were then subjected to immunoprecipitation with a HA-specific resin
(anti-HA), followed by immunoblotting with antibodies to the indicated proteins. (D) T98G cells were infected with a retrovirus expressing either HA-tagged
wild-type PDCD4 or HA-tagged PDCD4 mutants, as indicated. After serum deprivation (SD) for 72 hours, cells were activated with serum (SA) for the
indicated times in the presence of cycloheximide (CHX). Cells were then collected, and proteins were analyzed by immunoblotting with an antibody against
HA (left panels) to detect PDCD4 or with an antibody against CUL1 (right panels) to show normalization of the loading.
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To gain insight into the pathways involved in
the degradation of PDCD4, we reactivated
mitogen-deprived cells with serum in the pres-
ence of various drugs. LY294002, a phospho-
inositide 3-kinase (PI3K) inhibitor, prevented the
proteolysis of PDCD4 (Fig. 1C). The fact that
rapamycin, an inhibitor of mTOR (mammalian
target of rapamycin), but not PI3K or the
protein kinase AKT (which are both upstream
to mTOR), had the same effect as LY294002
indicated that the mTOR-ribosomal protein S6
kinase 1 (S6K1) pathway is involved in pro-
moting the degradation of PDCD4. The sta-
bilization of PDCD4 paralleled (i) the lack of
S6K1 phosphorylation and activation, (ii) the
lack of S6 phosphorylation, and (iii) the de-
creased phosphorylation of 4EBP1, a known
mTOR substrate. In contrast, the addition of
SB203580 and U1026, inhibitors of p38 and
extracellular signal–regulated kinases (ERKs),
respectively, had no effect on the degradation
of PDCD4.
The physical interaction between PDCD4
and bTRCP observed by mass spectrometry
suggests that SCFbTRCP is the ubiquitin ligase
targeting PDCD4 for degradation. This interac-
tion is specific, because bTRCP1 and bTRCP2
were the only F-box proteins that coimmuno-
precipitated with PDCD4 (fig. S2). Furthermore,
PDCD4 contains a canonical bTRCP-binding
motif ED70SGRGDS76 (10) in human PDCD4^
(fig. S3A). In all substrates investigated so far,
the two serine residues in the DSGXX(X)S degron
(where X represents any amino acid) must be
phosphorylated to allow recognition by bTRCP
(11). In many bTRCP substrates, phosphoryl-
ation on residues surrounding the degron pro-
motes the phosphorylation of the two serine
residues present in the degron (1). The putative
bTRCP-binding motif in PDCD4 is immediate-
ly preceded by a Ser that is part of a canonical
RXRXXS phosphorylation consensus site for
S6K1 (R62LRKNS67 in human PDCD4) (fig. S3B).
We generated a number of PDCD4 mutants Eall
with hemagglutinin epitope (HA) tags^ in which
Ser67, Ser71, or Ser76 were mutated individually
or in various combinations to Ala (e.g., Ser67
to Ala, S67A) (fig. S3C). After expression of
these proteins in human embryonic kidney
HEK293T cells, we immunoprecipitated them
with HA-specific resin. Although wild-type
PDCD4 immunoprecipitated efficiently with
bTRCP1, the PDCD4(S71A), PDCD4(S76A),
and PDCD4(S71/76A) mutants did not (Fig. 2A).
This suggests that Ser71 and Ser76 may be phos-
phorylated in vivo and may mediate the binding
to bTRCP. Accordingly, a peptide (amino acids
65 to 79) from PDCD4 containing both phos-
phorylated Ser71 and Ser76 efficiently bound
bTRCP1 (but not FBXW5 and FBXW7), but a
corresponding nonphosphorylated peptide did
not (Fig. 2B).
Compared with the wild-type protein,
PDCD4(S67A) displayed a markedly reduced
binding (Fig. 2A). To investigate whether Ser67
is phosphorylated in cells, we used a phospho-
specific antibody that recognizes the S6K1
phospho-consensus motif RXRXXpS (12). This
antibody recognized wild-type PDCD4 but not
PDCD4(S67A) or PDCD4(S67/71A) (Fig. 2A).
Notably, PDCD4 appeared to be phosphorylated
on Ser67 and associated with bTRCP1 in activated
cells but not in serum-deprived cells (Fig. 2C).
Compared with wild-type PDCD4, the half-
lives of PDCD4 mutants were increased in ac-
Fig. 3. Control of ubiq-
uitylation and degrada-
tion of PDCD4 by bTRCP
and S6K1. (A) T98G
cells were transfected
twice with siRNA mole-
cules to a nonrelevant
mRNA (LacZ) or to both
bTRCP1 and bTRCP2
mRNA. Cells were de-
prived of serum (SD) for
36 hours and then acti-
vated with serum (SA) for
the indicated hours. Lanes
1 and 7 show extracts from
asynchronously growing
cells (AS). Protein extracts
were probed with anti-
bodies to the indicated
proteins. (B) The experi-
ment was performed as
in (A), except that effects
with a dsRNA oligo to
S6K1 (lanes 7 to 12)
were compared with those having an oligomer targeting a nonrelevant mRNA
(lanes 1 to 6). (C) HEK293T cells were transfected with either HA-tagged PDCD4
or HA-tagged PDCD4(S67/71A) together with wild-type (WT), kinase-defective
T229A (KD), or T389E (CA) HA-tagged S6K1. Cell extracts were then sub-
jected to immunoblotting with antibodies to the indicated proteins. (D)
Unlabeled in vitro translated HA-tagged PDCD4 [WT or PDCD4(S67/71A)]
was immunoprecipitated with HA-specific resin (anti-HA), incubated with
purified recombinant S6K1 or PLK1 at 30-C for the indicated times, and
immunoblotted with antibodies to the indicated proteins (12). (E) In vitro
ubiquitin ligation assay of 35S-labeled in vitro translated PDCD4 [WT or
PDCD4(S67/71A)] was conducted in the presence or absence of the fol-
lowing proteins (used in different combinations as indicated): unlabeled in
vitro translated bTRCP, unlabeled in vitro translated FBXW5, purified
recombinant S6K1, or purified recombinant PLK1. Samples were incubated
at 30-C for 90 min, except those in lanes 1 and 11 that were immediately
added to sample buffer. The bracket on the left side of the top panels marks a ladder of bands corresponding to polyubiquitylated PDCD4.
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tivated T98G cells (Fig. 2D) and correlated with
their decreased binding to bTRCP (Fig. 2A). To
further test whether bTRCP might regulate the
stability of PDCD4, we used small interfering
RNA (siRNA) to reduce the expression of
bTRCP in T98G cells. We used a double-
stranded RNA (dsRNA) oligomer that efficiently
targets both bTRCP1 and bTRCP2 (3). De-
pletion of bTRCP inhibited the degradation of
PDCD4 after serum addition (Fig. 3A).
Because Ser67 is part of a canonical phos-
phorylation site for S6K1 and because rapamy-
cin and LY294002 inhibit PDCD4 degradation,
we tested whether S6K1 might promote the
bTRCP-mediated proteolysis of PDCD4. Inhi-
bition of expression of S6K1 in cultured cells
with a dsRNA oligomer (13) inhibited the phos-
phorylation (fig. S4) and degradation (Fig.
3B) of PDCD4. We also examined the ef-
fects of forced S6K1 expression on PDCD4
stability in HEK293 cells (Fig. 3C). Expres-
sion of wild-type S6K1 slightly reduced the
amounts of endogenous and exogenous PDCD4,
whereas the constitutively active (CA) S6K1 mu-
tant (T389E) had a stronger effect. A kinase-
defective (KD) S6K1 mutant (T229A) increased
the abundance of PDCD4. Overexpression of
wild-type S6K1 or S6K1 mutants had no ef-
fect on PDCD4(S67/71A) abundance, further
corroborating the importance of these two
residues in PDCD4 stability. The phosphoryl-
ation of PDCD4 on Ser67 by S6K1 was con-
firmed in a kinase assay using purified proteins
(Fig. 3D). We propose that, in response to
mitogens, S6K1 is activated and phosphoryl-
ates PDCD4 on Ser67. This event, in turn, pro-
motes the phosphorylation of Ser71 and Ser76
(by S6K1 or another kinase) and allows binding
to bTRCP.
We reconstituted the ubiquitylation of
PDCD4 in vitro. Wild-type PDCD4, but not
the PDCD4(S67/71A) mutant, was efficiently
ubiquitylated only when both bTRCP1 and
S6K1 were present in the reaction mix (Fig.
3E and fig. S5). A different F-box protein,
FBXW5, or a different kinase, PLK1, were un-
able to trigger the ubiquitylation of PDCD4
(Fig. 3E).
PDCD4 inhibits the cap-dependent transla-
tion of a luciferase mRNA with a stem-loop
structured 5¶UTR (pCMV-SL-LUC) more effi-
Fig. 4. Requirement of PDCD4 degradation for efficient protein translation, cell growth, and cell cycle progression.
(A) T98G cells were transfected with the pCMV-SL-LUC reporter plasmid together with a pRL-null Renilla luciferase
plasmid (for normalization) and constructs for the indicated proteins. Cells were allowed to recover for 18 hours
and then were serum starved. Twenty-four hours later, cells were restimulated with serum for an additional 20
hours. Luciferase activities were measured by a dual-luciferase assay, and the luciferase/renilla light-unit ratio was
calculated. The value of the sample transfected with an empty vector (EV) was set at 100%. Data are presented as
the means T SEM of three independent experiments (in triplicate). Amounts of exogenously expressed proteins
(analyzed by immunoblotting with the indicated antibodies) are shown in the upper panels. (B) T98G cells were
infected with a retrovirus expressing green fluorescent protein (GFP) and HA-tagged wild-type PDCD4 or HA-
tagged PDCD4(S67/71A). Cells expressing low levels of PDCD4 (only about three times endogenous PDCD4) were
isolated by fluorescence-activated cell sorting (FACS) (using GFP as a marker). After 72 hours of serum
deprivation (SD), cells were activated with serum (SA) for the indicated times. Cells were harvested and analyzed
by immunoblotting. (C) A representative experiment performed as in (B). Cell size was determined by FACS
(forward scatter) in cells deprived of serum (SD) and 12 hours after serum addition (SA). (D) The experiment was
performed as in (B). Four hours after serum addition (SA), whole-cell extracts (WCE) were either subjected directly
to immunoblotting or to immunoprecipitation (IP) with an antibody against eIF4A, followed by immunoblotting with antibodies to the indicated proteins. (E)
Model of how bTRCP and S6K1 control protein translation and cell size by promoting the degradation of PDCD4. For general reviews about protein
translation, see references (14–16).
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ciently than a nonstructured luciferase reporter
(8). To study the biological significance of
PDCD4 proteolysis, PDCD4 (wild-type or the
S67/71A mutant) and CA S6K1 expression
plasmids, as well as the pCMV-SL-LUC plas-
mid, were transiently transfected into T98G
cells in various combinations, and then lu-
ciferase activities were measured (Fig. 4A).
PDCD4(S67/71A) inhibited translation more
efficiently than wild-type PDCD4, in agreement
with its higher expression level after serum
addition. Accordingly, silencing of bTRCP in-
hibited luciferase activity (fig. S6). In contrast,
expression of CA S6K1 increased translation
(Fig. 4A). Whereas wild-type PDCD4 poorly
counteracted the effect of CA S6K1, expression
of PDCD4(S67/71A) completely neutralized
the stimulation by CA S6K1. All together,
these results show that the regulated degrada-
tion of PDCD4 positively modulates protein
translation in vivo.
We also infected T98G cells with retrovi-
ruses expressing HA-tagged wild-type PDCD4
or HA-tagged PDCD4(S67/71A). Cells were
deprived of serum for 72 hours and then re-
stimulated for various times (Fig. 4B). Expres-
sion of PDCD4(S67/71A) induced a slower
accumulation of cyclin D1, cyclin A, and
SKP2, and a slower degradation of p27. Thus,
expression of PDCD4(S67/71A) delays the G1-
to-S phase transition of the cell cycle. Because
S6K1 regulates cell growth (14, 15), we mea-
sured cell size by flow cytometry. After serum
stimulation, cells expressing PDCD4(S67/71A)
displayed decreased cell size relative to cells
expressing wild-type PDCD4 (Fig. 4C).
Finally, we investigated how the presence of
larger amounts of PDCD4 influences the binding
between eIF4A and eIF4G. In response to serum,
when PDCD4 was degraded, the association
between eIF4A and eIF4G increased more than
twofold (Fig. 4D). However, in cells expressing
PDCD4(S67/71A), this increase was no longer
evident, correlating with the observed 950%
inhibition of translation (Fig. 4A).
We propose that the degradation of PDCD4
in mitogen-stimulated cells is necessary for ef-
ficient protein translation, which is a prerequisite
for cell growth and, consequently, cell prolifer-
ation (16, 17) (Fig. 4E). Moreover, our findings
implicate S6K1 and SCFbTRCP in the regulation
of PDCD4 degradation and highlight the im-
portance of the ubiquitin system in the control
of translation initiation in response to mitogens.
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Functional Delivery of a Cytosolic
tRNA into Mutant Mitochondria
of Human Cells
Bidesh Mahata,1 Saikat Mukherjee,1 Sumita Mishra,2 Arun Bandyopadhyay,2 Samit Adhya1*
Many maternally inherited and incurable neuromyopathies are caused by mutations in mitochondrial
(mt) transfer RNA (tRNA) genes. Kinetoplastid protozoa, including Leishmania, have evolved specialized
systems for importing nucleus-encoded tRNAs into mitochondria. We found that the Leishmania RNA
import complex (RIC) could enter human cells by a caveolin-1–dependent pathway, where it induced
import of endogenous cytosolic tRNAs, including tRNALys, and restored mitochondrial function in a
cybrid harboring a mutant mt tRNALys (MT-TK) gene. The use of protein complexes to modulate
mitochondrial function may help in the management of such genetic disorders.
T
he A8344G mutation (A to G nucleotide
mutation at position 8344) in the MT-TK
gene in myoclonic epilepsy with ragged
red fibers (MERFF) (1) causes a substantial
reduction in the rate of translation of most
mitochondrial mRNAs, as well as the accumu-
lation of aberrant translation products (2),
which results from inefficient aminoacylation
of (3) and/or codon recognition by (4) the mu-
tant tRNA. More severe defects are observed
in patients possessing deletions of this gene:
for example, in Kearns-Sayre syndrome (KSS),
a 1.9-kb mitochondrial deletion covers the
MT-TK gene, as well as the neighboring CO2,
CO3, ATP6, and ATP8 genes (5). Cytoplasmic
hybrids (cybrids), derived from such patients
and carrying mutant mitochondria, are good in
vitro models for monitoring the efficacy of
correctional protocols. Partial rescue of mito-
chondrial function in cybrids, and in primary
fibroblasts from MERRF patients, by transfec-
tion of variants of yeast tRNALys genes has been
reported (6), but this approach suffers from low
efficiency, variability, and toxicity of the
transfection vehicle.
The RNA import complex (RIC), iso-
lated from the inner membrane of Leishmania
mitochondria, is a large (Mr È 600 kD) multi-
subunit aggregate containing several tRNA
binding proteins (fig. S1 and table S2) that is
active for specific, adenosine triphosphate
(ATP)–dependent translocation of tRNAs (7, 11).
Human cytoplasmic tRNALys(UUU) is im-
ported into the mitochondria of transgenic
Trypanosoma brucei (8) and transiently trans-
fected L. tropica (9), as well as into isolated
Leishmania mitochondria (9). Moreover, puri-
fied RIC induces import of the same tRNA
into human mitochondria in vitro (10). The
imported tRNA undergoes multiple rounds of
lysylation within the organelle and directly
donates lysine to the translating ribosome,
correcting the translational defects in MERRF-
derived mutant mitochondria (10). We tested
the hypothesis that RIC can be used to induce
functional tRNA import in whole cells.
To monitor uptake of RIC, we incubated
monolayer cultures of either the human hepa-
tocarcinoma (Hep) G2 cell line or cybrids
containing wild-type (LB58), MERRF patient–
derived (LB64), or KSS (FLP32.39) mitochon-
dria with affinity-purified fluorescent-tagged
RIC (11), and live cells were imaged at various
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